Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
114.64
+0.70 (0.61%)
Dec 20, 2024, 4:00 PM EST - Market closed
Ligand Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 152.42 | 131.31 | 196.25 | 241.54 | 163.56 | 120.28 | Upgrade
|
Revenue Growth (YoY) | -0.76% | -33.09% | -18.75% | 47.68% | 35.98% | -52.17% | Upgrade
|
Cost of Revenue | 32.37 | 35.05 | 88.91 | 94.28 | 70.92 | 67.26 | Upgrade
|
Gross Profit | 120.06 | 96.27 | 107.34 | 147.26 | 92.64 | 53.03 | Upgrade
|
Selling, General & Admin | 69.04 | 52.79 | 70.06 | 46.79 | 39.31 | 41.88 | Upgrade
|
Other Operating Expenses | - | - | - | - | 0.6 | - | Upgrade
|
Operating Expenses | 102.08 | 86.44 | 104.3 | 81.01 | 51.55 | 58.75 | Upgrade
|
Operating Income | 17.98 | 9.82 | 3.04 | 66.25 | 41.09 | -5.72 | Upgrade
|
Interest Expense | -2.29 | -0.66 | -1.8 | -19.62 | -27.42 | -35.75 | Upgrade
|
Interest & Investment Income | 7.82 | 7.71 | 2.05 | 0.89 | 8.08 | 28.43 | Upgrade
|
Other Non Operating Income (Expenses) | -52.23 | -0.78 | -0.01 | -0.35 | 2.53 | -4.17 | Upgrade
|
EBT Excluding Unusual Items | -28.72 | 16.1 | 3.28 | 47.17 | 24.28 | -17.21 | Upgrade
|
Merger & Restructuring Charges | - | - | - | - | -20.7 | - | Upgrade
|
Gain (Loss) on Sale of Investments | 114.95 | 46.37 | 28.54 | -5.26 | -16.93 | 1.05 | Upgrade
|
Gain (Loss) on Sale of Assets | - | 2.12 | - | - | 17.11 | 812.8 | Upgrade
|
Asset Writedown | -27.42 | -0.92 | - | - | - | - | Upgrade
|
Other Unusual Items | - | - | 4.19 | 30.3 | -2.47 | - | Upgrade
|
Pretax Income | 58.82 | 63.66 | 36.01 | 72.21 | 1.29 | 796.64 | Upgrade
|
Income Tax Expense | 13.57 | 9.84 | 41.23 | -4.15 | -5.31 | 167.34 | Upgrade
|
Earnings From Continuing Operations | 45.24 | 53.82 | -5.22 | 76.35 | 6.6 | 629.3 | Upgrade
|
Earnings From Discontinued Operations | - | -1.67 | -28.14 | -19.22 | -9.58 | - | Upgrade
|
Net Income to Company | 45.24 | 52.15 | -33.36 | 57.14 | -2.99 | 629.3 | Upgrade
|
Net Income | 45.24 | 52.15 | -33.36 | 57.14 | -2.99 | 629.3 | Upgrade
|
Net Income to Common | 45.24 | 52.15 | -33.36 | 57.14 | -2.99 | 629.3 | Upgrade
|
Net Income Growth | 174.52% | - | - | - | - | 339.09% | Upgrade
|
Shares Outstanding (Basic) | 18 | 17 | 17 | 17 | 16 | 19 | Upgrade
|
Shares Outstanding (Diluted) | 18 | 18 | 17 | 17 | 17 | 20 | Upgrade
|
Shares Change (YoY) | 5.70% | 5.27% | -2.19% | 2.50% | -14.84% | -17.91% | Upgrade
|
EPS (Basic) | 2.53 | 3.02 | -1.98 | 3.44 | -0.18 | 33.13 | Upgrade
|
EPS (Diluted) | 2.47 | 2.94 | -1.98 | 3.32 | -0.18 | 31.85 | Upgrade
|
EPS Growth | 160.46% | - | - | - | - | 434.40% | Upgrade
|
Free Cash Flow | 75.12 | 46.06 | 119.93 | 70.04 | 50.13 | -31.89 | Upgrade
|
Free Cash Flow Per Share | 4.09 | 2.59 | 7.11 | 4.06 | 2.98 | -1.61 | Upgrade
|
Gross Margin | 78.77% | 73.31% | 54.69% | 60.97% | 56.64% | 44.09% | Upgrade
|
Operating Margin | 11.79% | 7.48% | 1.55% | 27.43% | 25.12% | -4.76% | Upgrade
|
Profit Margin | 29.68% | 39.72% | -17.00% | 23.66% | -1.82% | 523.19% | Upgrade
|
Free Cash Flow Margin | 49.28% | 35.07% | 61.11% | 29.00% | 30.65% | -26.51% | Upgrade
|
EBITDA | 52.63 | 45.46 | 54.41 | 117.2 | 69.05 | 38.01 | Upgrade
|
EBITDA Margin | 34.53% | 34.62% | 27.72% | 48.52% | 42.22% | 31.60% | Upgrade
|
D&A For EBITDA | 34.65 | 35.64 | 51.37 | 50.95 | 27.97 | 43.73 | Upgrade
|
EBIT | 17.98 | 9.82 | 3.04 | 66.25 | 41.09 | -5.72 | Upgrade
|
EBIT Margin | 11.79% | 7.48% | 1.55% | 27.43% | 25.12% | -4.76% | Upgrade
|
Effective Tax Rate | 23.07% | 15.46% | 114.49% | - | - | 21.01% | Upgrade
|
Revenue as Reported | 152.42 | 131.31 | 196.25 | 241.54 | 163.56 | 120.28 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.